Systemic Steroid Treatment for Imatinib‐Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study
EJ Kim, MH Ryu, SR Park, MY Beck, WJ Lee… - The …, 2020 - academic.oup.com
Background To achieve optimal clinical outcomes in patients with gastrointestinal stromal
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
[HTML][HTML] Systemic Steroid Treatment for Imatinib‐Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study
EJ Kim, MH Ryu, SR Park, MY Beck, WJ Lee… - The …, 2020 - ncbi.nlm.nih.gov
Background To achieve optimal clinical outcomes in patients with gastrointestinal stromal
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study
EJ Kim, MH Ryu, SR Park, MY Beck… - The …, 2020 - pubmed.ncbi.nlm.nih.gov
Background To achieve optimal clinical outcomes in patients with gastrointestinal stromal
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
EJ Kim, MH Ryu, SR Park, MY Beck, WJ Lee… - The …, 2020 - europepmc.org
Background To achieve optimal clinical outcomes in patients with gastrointestinal stromal
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
Systemic Steroid Treatment for Imatinib‐Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
EJ Kim, MH Ryu, SR Park, MY Beck, WJ Lee… - …, 2020 - search.ebscohost.com
Background: To achieve optimal clinical outcomes in patients with gastrointestinal stromal
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
[PDF][PDF] Systemic Steroid Treatment for Imatinib‐Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study
EJ Kim, MH Ryu, SR Park, MY Beck, WJ Lee… - The …, 2020 - Wiley Online Library
Background To achieve optimal clinical outcomes in patients with gastrointestinal stromal
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
EJ Kim, MH Ryu, SR Park, MY Beck, WJ Lee… - The …, 2020 - europepmc.org
Background To achieve optimal clinical outcomes in patients with gastrointestinal stromal
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …
tumor (GIST), it is crucial to maintain sufficient dosing of imatinib. Skin rash is a common …